

**MDA/GD/0072  
May 2026  
First Edition**

# **MEDICAL DEVICE GUIDANCE DOCUMENT**

## **CHANGE MANAGEMENT FOR REGISTERED MEDICAL DEVICES**



**Medical Device Authority**  
MINISTRY OF HEALTH MALAYSIA

## CONTENTS

PREFACE	4
1. Introduction	5
2. Scope	5
3. Terms and Definitions	6
4. General Principles	8
5. Categorisation and Assessment of Changes	
5.1 Categorisation of Changes	9
5.2 Flowchart for Categorisation of Changes	9
5.3 UDI-DI Triggers	10
5.4 Reporting of Changes	11
5.5 Non-Significant Changes Not Subject to Change Management	12
5.6 Changes that Require New Registration	13
6. Bundling of Changes	
6.1 Single or Multiple Type of Changes Under a Single Application	13
6.2 Single or Multiple Type of Change Changes Under Multiple Applications	13
6.3 Examples of Scenarios involving Single or Multiple Types of Changes under Multiple Applications	14
7. Updates to Registered Device Information Prior to Re-Registration	15
8. Predetermined Change Control Plan (PCCP) of SaMD	16
9. Replacement Reagent and Instrument Family Policy	
9.1 General Eligibility Criteria	16
9.2 Additional Criteria for Instrument Grouping (Addition of a New Instrument)	17
9.3 Additional Criteria for Replacement Reagent (Extension of a Registered Assay)	17
10. Change Management Fees	18
11. Turn Around Time	19
12. Implementation of changes	19
<b>ANNEX A:</b>	
Main Flowchart - General Type of Changes to Medical Devices and In Vitro Diagnostic (IVD) Medical Devices (informative)	
Figure A.1 Overview Flowchart of Types of Changes	20
<b>ANNEX B:</b>	
Flowchart A to G - Categorisation of Change Types and Supporting Documentation Requirements	
Figure B.1: Flowchart A - Changes in Manufacturing Processes, Facility and/or Quality Management System (including QC) for Medical Devices and In Vitro Diagnostic (IVD) Medical Devices	21
Table B.1: Flowchart A - Change Categories and Required Supporting Documentation	22-26
Figure B.2: Flowchart B - Changes in Design for Medical Devices and In Vitro Diagnostic (IVD) Medical Devices	27

Table B.2: Flowchart B - Change Categories and Required Supporting Documentation	28-31
Figure B.3: Flowchart C- Change to Sterilisation Facility and its Process and/or Quality Management System	32
Table B.3: Flowchart C - Change Categories and Required Supporting Documentation	33-37
Figure B.4: Flowchart D - Changes to Software for Medical Devices	38
Table B.4: Flowchart D - Change Categories and Required Supporting Documentation	39-45
Figure B.5: Flowchart E1- Changes in Materials for General Medical Devices	46
Table B.5: Flowchart E1 Change Categories and Required Supporting Documentation	47-50
Figure B.6: Flowchart E2- Changes in Materials for In Vitro Diagnostic (IVD) Medical Devices	50
Table B.6: Flowchart E2 - Change Categories and Required Supporting Documentation	51-53
Figure B.7: Flowchart F- Changes to Labelling of Medical Devices and In Vitro Diagnostic (IVD) Medical Devices	54
Table B.7: Flowchart F - Change Categories and Required Supporting Documentation	55-59
Figure B.8: Flowchart G - Changes to Registered Medical Devices and In Vitro Diagnostic (IVD) Medical Devices registration information	60
Table B.8: Flowchart G - Change Categories and Required Supporting Documentation	61-63

## **PREFACE**

This Guidance Document was prepared by the Medical Device Authority (MDA) to help the industry and healthcare professionals in their quest to comply with the Medical Device Act 2012 (Act 737) and the regulations under it.

This Guidance Document shall be read in conjunction with the current laws and regulations used in Malaysia, which include but not limited to the following-

- a) Medical Device Act 2012 (Act 737); and
- b) Medical Device Regulations 2012.

In this Guidance Document, the following verbal forms are used:

- “shall” indicates a requirement;
- “should” indicates a recommendation;
- “may” indicates a permission; and
- “can” indicates a possibility or a capability.

Irrespective of the requirements of this Guidance Document, MDA has the right to request for information or material, or define conditions not specifically described in this document that is deemed necessary for the purpose of regulatory control.

MDA has put much effort into ensuring the accuracy and completeness of this guidance document. In the event of any contradiction between the contents of this document and any written law, the latter should take precedence.

MDA reserves the right to amend any part of the guidance document from time to time.

## **CONTACT INFORMATION**

For further information, please contact:

### **MEDICAL DEVICE AUTHORITY**

Ministry of Health Malaysia  
Level 6, Prima 9, Prima Avenue II  
Blok 3547, Persiaran APEC  
63000 Cyberjaya, Selangor  
MALAYSIA

Tel: +603-8230 0300

Fax: +603-8230 0200

Email: <https://femes.mda.gov.my/>

Website: <http://www.mda.gov.my>

## CHANGE MANAGEMENT FOR REGISTERED MEDICAL DEVICES

### 1. Introduction

During its lifecycle, a medical device may undergo various changes. Any modifications or changes made to a registered medical device must align with the essential principles of safety and/or performance, enabling a risk-based regulatory system to effectively control the associated market risks.

A manufacturer is obligated to assess the impact of any modification to a medical device on the patient, practitioner, and/or user. This assessment determines whether the change is anticipated to affect the device's safety, performance, or effectiveness, or the arrangements established to maintain quality system compliance with relevant standards (e.g., design verification, design validation, human factors, organizational structure, facility additions, deletions, or relocations), and/or applicable regulatory requirements. This is crucial for ensuring the continued safety, performance, and effectiveness of the medical device.

This document outlines general principles, categorization, reporting, and alternative pathways for managing changes. It employs a risk-based approach with illustrative examples.

### 2. Scope

This document applies to all registered medical devices under the Act 737 and outlines key considerations for manufacturers when a device undergoes any changes or modifications. It is also applicable when a registered medical device requires changes, or proposed changes, due to a mandatory reportable problem (MPR) or field corrective action (FCA) in accordance with Section 40 or Section 41 of Act 737.

Apart from Change Management (CM) submissions made in accordance with the applicable categories of change, the manufacturer may also update the information and supporting documents of a registered medical device prior to re-registration. Such updates shall be carried out through the Change Management module while the registration certificate remains valid.

In summary, the Change Management process applies to:

1. Any changes to a registered medical device; or
2. Updates arising from post-market issues, including reportable incidents and field corrective actions; or
3. Updates to information or documents required in preparation for re-registration.

### 3. Terms and Definitions

For the purposes of this document, the terms and definitions provided in Act 737, its subsidiary regulations, and the following definitions shall apply.

#### 3.1 Critical Supplier

A supplier delivering materials, components, or services, that may influence the safety and performance of the product.

**Note 1:**

In the context of QMS, a critical supplier is one whose product or service, if it fails to meet specified manufacturer's requirements, could result in an unreasonable risk to the patient, clinician, or others, or cause significant degradation in performance. This definition also encompasses suppliers of services essential for complying with Quality Management System (QMS) or regulatory requirements.

**Note 2:**

The following is a non-exhaustive list of examples of critical suppliers:

- suppliers of certain types of raw materials, including; medicinal substances, active ingredients, and material of animal, microbial or recombinant origin.
- suppliers of sterilisation services.
- suppliers of design and development activities for manufacturers holding, or applying for, a full quality assurance Conformity Assessment certificate.
- suppliers that carry out all stages of production and supply on behalf of the manufacturer.

[Source: GHTF/SG4/N84 Guidelines for Regulatory Auditing of Quality Management Systems of Medical Device Manufacturers, Additional section 4. (Critical supplier details), Therapeutic Goods Administration, Department of Health, Disability and Ageing, Australian Government]

#### 3.1 Editorial changes

Simple clarifications that do not alter the substantive meaning of the information. Editorial changes may include punctuation changes, grammar corrections, typographical correction, reordering existing material, rephrasing sentences that do not alter the content and adding headers for ease of use.

#### 3.2 Intended use

The objective intent of the manufacturer regarding the use of a product, process or service as reflected in the specifications, instructions and information provided by the manufacturer.

[Source: Medical Device Regulations 2012]

#### 3.3 In Vitro Diagnostic (IVD) Medical Devices

In vitro diagnostic tests are used for in vitro examination of specimens derived from the human body to provide information for screening, diagnosis, or treatment monitoring purposes.

Includes any reagent, reagent product, calibrator, control material, kit, instrument, apparatus, equipment or system, whether used alone or in combination with any other reagent, reagent product, calibrator, control material, kit, instrument, apparatus, equipment or system, that is intended by its manufacturer to be used in vitro for the examination of any specimen, including any blood or tissue donation, derived from the human body, solely

or principally for the purpose of providing information:

- a) concerning a physiological or pathological state or a congenital abnormality
- b) to determine the safety and compatibility of any blood or tissue donation with a potential recipient thereof; or
- c) to monitor therapeutic measures; and includes a specimen receptacle.

[SOURCE: Guidance Document MDA/GD/0001 In-Vitro Diagnostic (IVD) Medical Device Classification System]

### **3.4 Labelling**

The label, instructions for use, and any other information that is related to identification, technical description, intended purpose and proper use of the medical device, but excluding shipping documents.

### **3.5 Manufacturer**

As defined in Section 2 of the Act 737.

### **3.6 MeDC@St**

A web-based, centralized online application system administered by the MDA, used for submission and management of establishment licences, medical device registrations, change management applications, and related regulatory filings.

### **3.7 Medical device**

As defined in Section 2 of Act 737 and MDA/GD/0006: Guidance on the Definition of Medical Device.

### **3.8 Multiple application**

A consolidated Change Management submission that encompasses two or more Medical Device Registration Certificate numbers. This submission is applicable when the same type of change affects multiple registered medical devices.

### **3.9 Non-significant change**

Any change that has little or no potential to affect the safety and/or performance/effectiveness of the medical device.

[SOURCE: Guidance Document GHWP/WG2-WG1-WG3/F001:2024 Change management to registered Medical Devices]

### **3.10 Quality Control (QC)**

It is part of quality management focused on fulfilling quality requirements.

[SOURCE: (ISO 9000 Quality management)]

### **3.11 Risk management**

A systematic application of management policies, procedures and practices to the tasks of analysing, evaluating, controlling and monitoring risk.

[SOURCE: ISO 14971:2019 Medical devices - Application of risk management to medical devices]

### **3.12 Single application**

A Change Management submission involving only one Medical Device Registration Certificate number.

### **3.13 Significant change**

Any change that could reasonably be expected to affect the safety and/or performance/effectiveness of a medical device or its conformity with the essential principles.

[SOURCE: Guidance Document GHWP/WG2-WG1-WG3/F001:2024 Change management to registered Medical Devices]

### **3.14 Software as a medical device (SaMD)**

Software as intended to be used for one or more medical purposes that perform these purposes without being part of a hardware medical device.

**Notes:**

- a) SaMD is a medical device and includes in-vitro diagnostic (IVD) medical devices;
- b) SaMD is capable of running on general purpose (non-medical purpose) computing platforms;
- c) "without being part of" means software not necessary for a hardware medical device to achieve its intended medical purpose;
- d) Software does not meet the definition of SaMD if its intended purpose is to drive a hardware medical device;
- e) SaMD may be used in combination (e.g., as a module) with other products including medical devices;
- f) SaMD may be interfaced with other medical devices, including hardware medical devices and other SaMD software, as well as general purpose software;
- g) Mobile apps that meet the definition above are considered SaMD.

[SOURCE: Guidance Document IMDRF, Software as a Medical Device (SaMD): Key Definitions]

## **4. General Principles**

For any change made to a registered medical device, the manufacturer shall evaluate:

- the device concerned;
- the potential impact of the change on patients, practitioners, and/or users;
- the implications of the change on the intended use or indications for use, risk classification, and device specifications.

Following this evaluation, the manufacturer shall determine whether the change may reasonably be expected to influence the safety, performance, or effectiveness of the device,

or its continued conformity with the Essential Principles and its overall risk–benefit profile throughout the device’s lifecycle.

## 5. Categorisation and Assessment of Changes

### 5.1 Categorisation of Changes

Changes to a registered medical device may be categorised as significant or non-significant, depending on the extent to which the changes impact the safety and/or performance of the device.

A significant change typically may:

- i. introduce risks to the patient and / or user that were not previously identified in the risk management file;
- ii. increase the probability of occurrence of existing hazards; or
- iii. modify the presentation of existing or new risks to the user, including those arising from labelling changes or new indications for use.

Significant changes may include, but are not limited to, changes to:

- i. the manufacturing process, facility, or equipment;
- ii. the manufacturing quality control procedures, including methods, tests, reference standards, or procedures used to control the quality, purity, and sterility of the device or the materials used in its manufacture;
- iii. the design of the device, including its performance characteristics, principles of operation, and specifications of materials, energy source, software, or accessories.

**Note:** Refer to Annex A for the complete list of significant changes.

A non-significant change is any change that has little or no potential to affect the safety and/or performance of the medical device.

### 5.2 Flowchart for Categorisation of Changes

The following section provides flowcharts to assist manufacturers in assessing a change to determine whether the change constitutes a significant change that needs to be reported to the MDA. Certain changes classified as non-significant may also require reporting, depending on their nature and impact.

The main flowchart in **Annex A** outlines the general categories of changes and offers practical guidance to support manufacturers in assessing whether a change may affect the safety and/or performance of a medical device.

Flowcharts A to G in **Annex B** present specific questions and decision pathways to further assist in determining whether a change should be categorised as significant or non-significant. These flowcharts, together with their accompanying explanations, are intended to clarify the decision-making process for change categorisation.

The summary of the flowcharts is provided in Table 1.

**Table 1. Summary of Flowchart Categorization based on Type of Changes**

<b>Flowchart</b>	<b>Changes</b>
<b>Main Flowchart</b>	General Type of Changes to Medical Devices and In Vitro Diagnostic (IVD) Medical Devices
<b>Flowchart A</b>	Changes in Manufacturing Processes, Facility and/or Quality Management System (including QC) for Medical Devices and In Vitro Diagnostic (IVD) Medical Devices
<b>Flowchart B</b>	Changes in Design for Medical Devices and In Vitro Diagnostic (IVD) Medical Devices
<b>Flowchart C</b>	Changes to Sterilisation Facility and its Process
<b>Flowchart D</b>	Changes to Software for Medical Devices
<b>Flowchart E1</b>	Changes in Materials for Medical Devices
<b>Flowchart E2</b>	Changes in Materials for In Vitro Diagnostic (IVD) Medical Devices
<b>Flowchart F</b>	Changes to Labelling of Medical Devices and In Vitro Diagnostic (IVD) Medical Devices
<b>Flowchart G</b>	Changes to Registered Medical Devices and In Vitro Diagnostic (IVD) Medical Devices registration information

### 5.3 UDI-DI Triggers

UDI-DI (Unique Device Identifier – Device Identifier) triggers are specific changes or events in a medical device’s characteristics, labelling, or packaging that necessitate the assignment of a new UDI-DI. These triggers ensure that each distinct version or model of a device is uniquely identifiable, avoiding misidentification and maintaining traceability throughout the device’s life cycle. If the same Device Identifier (DI) continues to be used for newer versions of a medical device after changes have been made, it may lead to misidentification of the device and/or ambiguity in its traceability.

A new UDI-DI should be assigned when changes are made to any of the following UDI-DI related device data elements:

- Brand name
- Device version or model
- Clinical size (including volume, length, gauge, diameter)
- Labelled as single-use
- Packaged as sterile
- Requirement for sterilisation before use
- Quantity of devices contained within a package
- Critical warnings or contraindications (e.g., contains latex or Bis(2-ethylhexyl) phthalate (DEHP))
- New or revised packaging configurations

When a change to a registered medical device necessitates a new UDI-DI, the manufacturer shall assess the change based on the flowchart Categorisation to determine the appropriate categories of change and apply for the applicable Change Management or a new pre-market submission, in accordance with the regulatory requirements.

#### 5.4 Reporting of changes

A manufacturer or Authorised Representative (AR) shall manage and assess all changes to a registered medical device according to their potential impact on safety and performance to determine the categorisation of change. Changes categorized as Significant Change shall be reported to MDA as explained in the Categorisation of Change Flowchart. The change will be subjected to evaluation and approval by MDA. For such changes, the affected medical device may only be placed on the market upon receipt of the MDA's approval.

Generally, non-significant changes do not require reporting to the MDA before implementation. However, referring to the Categorisation of Change Flowchart, for certain non-significant changes, notification to the MDA is required. This notification must be submitted with the necessary supporting documentation.

For non-significant changes that do not require notification to the MDA, the manufacturer or AR must maintain a documented assessment and supporting evidence within their Quality Management System (QMS) and/or technical documentation. This documentation is necessary to demonstrate the continued safety and intended performance of the device.

To assist manufacturers in determining the correct reporting pathway, Table 2 provides a recommended approach for reporting various types of changes.

**Table 2. Recommended Approach for Reporting Changes**

Type of Changes	Reporting Pathway
Significant Change	Changes that require evaluation and approval by the MDA prior to implementation and before the device is placed on the market.
Non-Significant Change – Notification Required	Changes that may be implemented immediately upon submission of complete documentation through MeDC@St.
Non-Significant Change – Notification Optional	Changes that do not require submission; however, the manufacturer may submit a notification voluntarily.
Non-Significant Change	Changes that do not require submission but must be fully documented within the manufacturer's QMS and/or technical documentation.

**Note:** QMS requirement: Manufacturer shall assess the changes, perform risk benefit of the product, document the changes and if applicable update the technical documentation.

All Change Management applications shall be submitted through MeDC@St. Manufacturers or AR are required to provide complete supporting documentation as specified in Annex B.

Manufacturers or AR are reminded that the determination of required documentation for a change management shall be based on all changes submitted, and not solely on an individual category of change.

All Change Management applications shall be supported with complete documents. Where any supporting document is unavailable, a clear and valid justification shall be provided.

### **5.5 Non-Significant Changes Not Subject to Change Management**

The following types of changes are considered non-significant and are not subject to formal change management procedures:

- Changes to raw material suppliers (excluding medicinal substances and biological material suppliers) provided that the change does not affect the specifications of the registered medical device.
- Editorial changes to the labelling that do not affect the device's intended use, safety, or performance.
- Rephrasing or rearrangement of information in the labelling without altering the meaning of the information remains unchanged.
- Labelling changes involving the addition and/or removal of languages that are not required by the MDA.
- Labelling changes involving the addition, removal, or modification of references to regulatory clearances or authorisations, provided that such changes do not affect the device's registration.
- Labelling changes involving the addition, removal, or modification of barcodes, provided that such changes do not alter the registered device's List of Configuration (LoC) information.
- Labelling changes that involve only layout, colour, font size, or design adjustments, provided there is no change to the prominence or content of the labelling.
- Labelling changes that update distributor information, including EU Authorised Representatives (AR), provided these changes do not affect the registered medical device information.
- Labelling changes to update Authorised Representative (AR) information, such as changes to the AR name, address, or ownership, provided that the amendment has been approved in the Establishment Licence (EL) Module by the MDA.

NOTE: This above list is non-exhaustive and may be subject to change by the Authority

These changes must still be documented within the manufacturer's Quality Management System (QMS) to demonstrate that the device continues to comply with regulatory and safety requirements.

## 5.6 Changes that Require New Registration

The following types of changes may require the manufacturers or AR to apply for new registration and subject to the regulatory assessment:

- a) Fundamental changes to a registered medical device that result in the device being considered as a new medical device, such as a complete change to its intended use or intended purpose previously approved;
- b) Change to the risk classification of a registered medical device;
- c) Addition of devices not considered a permissible variant according to the rules of grouping in Second Schedule of MDR 2012 and MDA/GD/0005, Product Grouping;
- d) Addition of variant(s) for Cluster (Class A and B) according to the rules of grouping in Second Schedule of MDR2012 and MDA/GD/0054 Product Grouping for In-Vitro Diagnostic (IVD) Medical Devices;
- e) Addition of medical devices with device proprietary names different from the registered devices, into a device listing. Unless the devices with different proprietary names qualify to be listed together under one listing based on MDA guidance documents on grouping criteria for medical devices registration.

## 6. Bundling of Changes

Significant and non-significant changes that require notification submission in MeDC@St may be bundled for regulatory submission purposes, provided the changes meet the requirements outlined in this guidance.

Bundling allows multiple related changes to be submitted together in a single application or across multiple applications, depending on the nature and scope of the changes. There are two types of bundling changes:

### 6.1 Single or Multiple Type of Changes Under a Single Application

When changes involve one or multiple types of changes applied to a single registration certificate, such changes may be bundled and submitted under one Change Management application.

### 6.2 Single or Multiple Type of Change Changes Under Multiple Applications

Bundling of one or multiple types of changes across multiple applications is only permitted for the following type of changes:

- Change in Manufacturer Name and/or Address.
- Change in Manufacturing Site Name and/or Address.
- Change in Sterilisation Site Name and/or Address.
- Change in Quality Management System (QMS) Information.

- Change in Brand or Proprietary Name.
- Change in Labelling Information.

The changes are permitted for the same changes for multiple types of changes for multiple registration certificate numbers.

Such bundling is allowed only when the same changes are applied consistently across multiple registered certificate numbers.

### 6.3 Examples of Scenarios Involving Single or Multiple Types of Changes under Multiple Applications

#### (a) Single Type of Change Under Multiple Application

Where a single type of change applies to multiple certificates.

Example scenario:

- Change in Manufacturer Name

Certificate No.	Current Manufacturer	Proposed Manufacturer
GAXXXX001	ABC Medical Sdn. Bhd.	XYZ Medical Sdn. Bhd.
GAXXXX002	ABC Medical Sdn. Bhd.	XYZ Medical Sdn. Bhd.
GAXXXX003	DEF Medical Sdn. Bhd.	XYZ Medical Sdn. Bhd.

All certificates involve a change in manufacturer to Manufacturer XYZ

#### (b) Multiple Type of Changes Under Multiple Applications

Where more than one type of change (e.g. manufacturer name, brand, and/or site address) is applied consistently across multiple certificates.

Example Scenario:

Certificate No.	Current Manufacturer	Proposed Manufacturer	Current Brand	Proposed Brand
GAXXXX010	Manufacturer A	Manufacturer B	Brand A	Brand B
GAXXXX011	Manufacturer A	Manufacturer B	Brand A	Brand B
GAXXXX012	Manufacturer C	Manufacturer B	Brand C	Brand B

In this case:

- All certificates involve a change in manufacturer to Manufacturer B; and
- All certificates involve a change in brand to Brand B.

Even though the existing manufacturers or brands differ among certificates, the **proposed change outcome** is the same across all applications. Therefore, the changes may be bundled under a single Change Management submission.

## 7. Updates to Registered Device Information Prior to Re-Registration

Apart from Change Management submissions made in accordance with the applicable categories of change, manufacturers may also update the information and supporting documents of a registered medical device prior to re-registration. Such updates shall be carried out through the Change Management module while the registration certificate remains valid. This change is classified as a non-significant change and must be notified to the MDA.

Only medical devices with fully updated and current information may proceed with re-registration. Manufacturers are responsible for ensuring that all required information and documents are updated at any time within the five-year validity period of the certificate, and that these updates are completed before submission of the re-registration application. Re-registration cannot proceed if any required information or document has not been updated.

For the purpose of re-registration, the following information and documents shall be updated according to device class:

- Class A Medical Devices
  - Declaration of Conformity (DoC)
  - Quality Management System (QMS) information
  - Post-Market Surveillance (PMS) information
- Class B, C, and D Medical Devices
  - Declaration of Conformity (DoC)
  - Quality Management System (QMS) information
  - Post-Market Surveillance (PMS) information
  - Clinical Evaluation Report (CER) or Clinical Performance Report (CPR)
  - Risk Management Report
  - CAB Report and Certificate

Manufacturers must ensure that all updates are completed and approved, where required, prior to initiating the re-registration process.

However, the MDA reserves the right to request additional information or documents if deemed necessary to support the evaluation and approval of the re-registration application.

## 8. Predetermined Change Control Plan (PCCP) of SaMD

Any changes to an approved Predetermined Change Control Plan (PCCP) that was submitted during the initial premarket review (new medical device registration application) shall be managed through a formal change management application.

A PCCP outlines the pre-specified elements of Software as a Medical Device (SaMD) that may be modified post-market, along with the associated methodology, data requirements, and verification/validation processes that ensure ongoing compliance with safety and performance principles. Once the PCCP has been reviewed and approved as part of the premarket submission, it forms part of the regulatory decision for the device.

Therefore, any subsequent change to the approved PCCP within the allowable change boundaries must be submitted to the MDA through a change management application to ensure that the revised PCCP remains appropriate, scientifically justified, and consistent with the device's intended use and risk classification.

The change management process allows the MDA to assess whether:

- The proposed modification to the PCCP continues to support the safe and effective performance of the device;
- The change remains within the originally approved regulatory framework; and
- Any new information, risks, or methodologies introduced are adequately controlled and documented.

This approach maintains regulatory oversight while enabling innovation and continuous improvement under a controlled and transparent mechanism.

NOTE: The comprehensive requirements for PCCP will be specified in a separate guidance document on Software as a Medical Device (SaMD).

## 9. Replacement Reagent and Instrument Grouping Approaches

The Replacement Reagent and Instrument Grouping expedites the availability of low to medium-risk assays on instruments within the same family.

The Reagent Replacement Grouping is a risk-based approach that relies on the manufacturer's Quality Management System (QMS), including risk-based assessments, and criteria, testing, and internal documentation for each reagent application, to allow low or medium risk reagents to be added to a registered instrument.

Aligned with the principles outlined in the Instrument Grouping, a new instrument may be added to a registered instrument family.

### 9.1 General Eligibility Criteria

To qualify for this criteria:

- The IVD test kit/assay and instrument shall be registered with MDA; and
- The changes do not significantly affect the safety, performance, or intended use of the test system; and

- The manufacturer has an established Quality Management System (QMS) to support risk assessment, verification/validation, and documentation; and
- The change involves class A and B IVDs only; and
- Verification and validation confirm equivalent performance to the registered medical device.

### **9.2 Additional Criteria for Instrument Grouping (Addition of a New Instrument)**

A new instrument may be added to an existing instrument grouping when it complies to the additional criteria below:

- It shares the same general architecture, design, detection method, and intended use as the approved master instrument.
- Differences such as throughput, user interface, or data storage do not affect assay performance.
- The new instrument's performance is verified and validated against acceptance criteria used for the master instrument.
- Comparative documentation (e.g., architecture, software, reaction conditions) demonstrates equivalence.

### **9.3 Additional Criteria for Replacement Reagent (Extension of a Registered Assay)**

Registered assay/test kit may be applied to another registered instrument or instrument grouping when:

- The intended use and detection principle are the same.
- The assay's key components, formulation, and performance characteristics are the same.
- The instrument is already approved or part of an approved grouping.
- The new combination has been verified and validated by the manufacturer to confirm comparable analytical and clinical performance.

If the device meets all the eligibility criteria outlined under the Replacement Reagent and Instrument Family, the changes can be proceeded through the Change Management process in accordance with MDA's regulatory requirements, supported by comparative documentation, risk assessment, and performance validation data.

Note: This approach does not apply if:-

- The assay or instrument is new and not previously approved.
- There is a change in measurement principle, detection method, or intended use.
- The device involves high-risk IVDs, blood banking, self-testing, or point-of-care use.
- There are significant reagent formulation changes or new sample types introduced.
- The instruments are classified as class A, whereas reagents and kits have different classification higher than Class A.

## 10. Change Management Fees

Submissions shall be accompanied by the applicable fee as specified in Table 3 below. Payment shall be made by the applicant after receiving approval of the Significant Change or acknowledgement of Non-Significant Change application from the MDA.

**Table 3. Change management fees**

Medical Device Risk Class	Significant Change (RM)	Non-Significant Change (RM)
Class A	50	30
Class B	500	30
Class C	1000	30
Class D	1500	30
Medical device that contains a medicinal product	2500	30

Table 4 provides examples of how fees are calculated for single and multiple change notifications, including both significant and non-significant changes. Fees are based on the type of change, device class, and the number of registration certificate numbers included in the application, with combined applications summing the fees for each change type.

**Table 4. Example of Calculation Fees for Change Management of Single and Multiple Applications**

No	Application	Calculation
1	Single application for one category (either significant or non-significant)	The applicant has submitted a single application for a significant change, Class B.  Calculation fee = Fee for significant change, Class B = RM 500
2	Single application for significant and non-significant changes	The applicant has submitted a single application covering both a significant change, Class B and a non-significant change, Class B.  Calculation fee = Fee for significant change, Class B + Fee for non-significant change, Class B = RM 500 + RM 30 = RM 530
3	Multiple applications for one category (either significant or non-significant)	The applicant has combined 3 registration certificate numbers under significant change, Class B.  Calculation fee = Number of registration certificate numbers × Fee for significant change, Class B = 3 × RM 500 = RM 1,500
4	Multiple applications for both significant and non-significant change	The applicant has combined 3 registration certificate numbers covering both significant change, Class B and non-significant change, Class B.

No	Application	Calculation
	non-significant changes	Calculation fee = (Number of registration certificates × Fee for significant change, Class B) + (Number of registration certificates × Fee for non-significant change, Class B) = 3 × RM 500 + 3 × RM 30 = RM 1,590

## 11. Turn Around Time

The turn-around time (TAT) for the evaluation of each Change Management application is outlined as follows:

**Table 5. Turn-Around Time for Change Management Applications**

Application Type	Significant Change	Non-Significant Change
Single Application for Single Type of Change	10 working days	No TAT, as the change may be implemented immediately.
Single Application for Multiple Type of Change	Until 45 working days	
Multiple Application	Until 45 working days	

The stated turn-around time applies upon submission of a complete application form together with all required supporting documents.

## 12. Implementation of changes

Where practicable, medical devices bearing the original version of the device information should be relabelled to reflect the updated version. Devices that have already been placed on the market or are held in inventory with the original version information may continue to be supplied after approval of the Change Management, provided they remain compliant with the applicable conformity assessment requirements. The manufacturer or AR shall establish communication to inform users of the latest changes to the medical device.


During the transition period, the manufacturer or AR shall ensure continued traceability and regulatory compliance by periodically notifying the Medical Device Authority (MDA) of the quantity and distribution status of devices bearing the original version information that remain in the market or in storage, and by ensuring that customers and users continue to have access to technical support and post-market surveillance (PMS) services under the updated version information.

Following approval of the Change Management, all newly imported devices shall bear the updated version information. However, existing stock with the original version information may continue to be distributed, subject to the traceability and reporting requirements.

Changes resulting from field corrective action (FCA), including those submitted in relation to open reportable adverse events or ongoing FCA, may be implemented immediately without prior approval from MDA.

**ANNEX A:**  
**(informative)**


**Main Flowchart - General Type of Changes to Medical Devices and In Vitro Diagnostic (IVD) Medical Devices**



**Figure A.1 Overview Flowchart of Types of Changes**

**ANNEX B: Flowchart A to G - Categorisation of Change Types and Supporting Documentation Requirements  
(normative)**

**FLOWCHART A**



**Figure B.1: Flowchart A - Changes in Manufacturing Processes, Facility and/or Quality Management System (including QC) for Medical Devices and In Vitro Diagnostic (IVD) Medical Devices**

**Table B.1: Flowchart A - Examples of Changes and Required Supporting Documentation**

Flowchart Change No.	Description	Change Category	Supporting Documents
<b>Change A1</b>	<p>Change in critical supplier with change in specification of registered medical device:</p> <p><i>Examples include:</i></p> <ul style="list-style-type: none"> <li>● <i>Change of the supplier of the antibody with a different manufacturing process.</i></li> <li>● <i>Change of supplier of plastic raw material of catheter.</i></li> </ul>	<b>Significant</b>	<ul style="list-style-type: none"> <li>● QMS certificate(s).</li> <li>● Summary of new manufacturing process.</li> <li>● Validation report covering new processes.</li> <li>● Pre-clinical study reports.</li> <li>● Software validation report (for software-based devices).</li> <li>● Clinical evaluation report.</li> <li>● Risk management report.</li> <li>● Change approval documents from recognised countries.</li> </ul>
<b>Change A1</b>	<p>Change to manufacturing processes (including outsourced processes), facility or equipment by the manufacturer and/or the critical supplier that affects the device's safety and/or performance</p> <p><i>Example of manufacturing process change (but not limited to):</i></p> <ul style="list-style-type: none"> <li>● <i>Change in the equipment used for cutting, resulting in the change in length of sutures.</i></li> <li>● <i>Moulding or cutting process modifications.</i></li> </ul>	<b>Significant</b>	<ul style="list-style-type: none"> <li>● QMS certificate(s).</li> <li>● Summary of new manufacturing process.</li> <li>● Validation report covering new processes.</li> <li>● Pre-clinical study reports.</li> <li>● Software validation report (for software-based devices).</li> <li>● Clinical evaluation report.</li> <li>● Risk management report.</li> <li>● Change approval documents from recognised countries.</li> </ul>

Flowchart Change No.	Description	Change Category	Supporting Documents
	<ul style="list-style-type: none"> <li>• <i>Change from centrifugation to filtration process which results in better molecule separation.</i></li> <li>• <i>Change of implant manufacturing process from casting to 3D printing.</i></li> <li>• <i>Change from manual to automated operation, without altering the device specification.</i></li> <li>• <i>Changes to the packaging process, which is considered part of manufacturing.</i></li> </ul>		
<b>Change A2</b>	Change in term of addition, deletion or relocation of manufacturing site with a change to manufacturing process	<b>Significant</b>	<ul style="list-style-type: none"> <li>• Declaration of Conformity.</li> <li>• QMS certificate(s).</li> <li>• Summary of new manufacturing process.</li> <li>• Risk management report.</li> <li>• Validation report covering new processes.</li> <li>• Change approval documents from recognised countries.</li> </ul>
<b>Change A3</b>	<p>Changes to manufacturing control procedures</p> <p><i>Examples include: modifications to test acceptance criteria, in-process inspections, or final quality checks, that may impact the safety and/or performance of the medical device.</i></p>	<b>Significant</b>	<ul style="list-style-type: none"> <li>• Risk management report.</li> <li>• Summary of new manufacturing process.</li> <li>• Validation report covering new processes.</li> <li>• Pre-clinical study reports.</li> </ul>


Flowchart Change No.	Description	Change Category	Supporting Documents
			<ul style="list-style-type: none"> <li>● Software validation report (<i>for software-based devices</i>).</li> <li>● Clinical evaluation report.</li> <li>● Change approval documents from recognised countries.</li> </ul>
<b>Notification A4</b>	Change in terms of addition / deletion / relocation of a manufacturing site without any change to the manufacturing process.	<b>Non-Significant, Notification Required</b>	<ul style="list-style-type: none"> <li>● QMS Certificate(s).</li> <li>● Declaration confirming no change to manufacturing process</li> <li>● Labelling.</li> <li>● Declaration of Conformity.</li> </ul>
<b>Notification A4</b>	<p>Changes in Manufacturing Site's Registered Name and Address (Administrative Office)</p> <p><i>Examples include: A change in the manufacturing site address without a physical move, due to administrative updates to the address.</i></p>	<b>Non-Significant, Notification Required</b>	<ul style="list-style-type: none"> <li>● QMS certificate(s).</li> <li>● Declaration confirming no change to manufacturing process.</li> <li>● Declaration of Conformity.</li> </ul>
<b>Notification A4</b>	Changes to QMS Validity Date	<b>Non-Significant, Notification Required</b>	<ul style="list-style-type: none"> <li>● QMS certificate(s).</li> <li>● Declaration of Conformity.</li> <li>● Declaration confirming no change to manufacturing process.</li> <li>● Labelling.</li> </ul>
<b>Notification A4</b>	Change to foreign legal manufacturer's name and/or address	<b>Non-Significant, Notification Required</b>	<ul style="list-style-type: none"> <li>● QMS certificate(s).</li> <li>● Declaration of Conformity.</li> <li>● Declaration confirming no change to manufacturing process.</li> <li>● Labelling.</li> </ul>

Flowchart Change No.	Description	Change Category	Supporting Documents
<b>Flowchart A</b>  <i>Note: these examples of nonsignificant changes do not affect safety and performance, hence no notification required.</i>	Change to manufacturing processes (including outsourced processes), facility, or equipment by the manufacturer and/or supplier that does not affect the device's safety or performance.  <i>Examples include: Change in a non-critical supplier with no change in finished product performance specifications.</i>	Non-Significant	N/A
	A supplier's manufacturing process, facility, or equipment changes, provided device specifications have not changed and incoming inspections to evaluate the material/equipment remain the same.	Non-Significant	N/A
	Changes to QMS Certificate  <i>Examples include:</i> <ul style="list-style-type: none"> <li>• <i>Change in conformity assessment body with no change in scope of certification</i></li> <li>• <i>Cancellation of QMS scope that does not impact device safety or performance</i></li> <li>• <i>Correction of typos, zip code, or other administrative errors on the certificate</i></li> </ul>	Non-Significant	N/A
	Changes to manufacturing QC process.  <i>Examples include:</i>	Non-Significant	N/A

Flowchart Change No.	Description	Change Category	Supporting Documents
	<ul style="list-style-type: none"> <li>• <i>Addition of new QC specifications or tests.</i></li> <li>• <i>A new QC specification tightened with additional tests to strengthen the QC process.</i></li> <li>• <i>Change of measuring or monitoring equipment without altering test parameters.</i></li> <li>• <i>Modification or addition of test acceptance criteria/methods that provide equivalent or better assurance of reliability.</i></li> </ul>		

NOTE: Please provide a justification if supporting documents cannot be provided.

**FLOWCHART B**



**Figure B.2: Flowchart B - Changes in Design for Medical Devices and In Vitro Diagnostic (IVD) Medical Devices**

**Table B.2: Flowchart B - Examples of Changes and Required Supporting Documentation**

Flowchart Change No.	Description	Change Category	Supporting Documents
<b>Change B1</b>	<p>Changes to control mechanisms or operating principles of a medical device.</p> <p><i>Examples include:</i></p> <ul style="list-style-type: none"> <li>• <i>Change in the source of energy used by the device.</i></li> <li>• <i>Change from a quantitative assay to a qualitative assay.</i></li> <li>• <i>Addition of a footswitch to an X-ray system that previously did not operate via a footswitch.</i></li> <li>• <i>Change of an RIA test to an ELISA test.</i></li> </ul>	<b>Significant</b>	<ul style="list-style-type: none"> <li>• Pre-clinical study reports.</li> <li>• Risk management report.</li> <li>• Clinical evaluation report.</li> <li>• Software validation report (<i>for software devices</i>).</li> <li>• Detailed summary of software changes (<i>for software devices</i>).</li> <li>• Labelling.</li> <li>• Change approval documents from recognised countries.</li> </ul>
<b>Change B2</b>	<p>Change in design characteristics/specifications allowing additional or broader time intended use and/or indications for use.</p> <p><i>Examples include:</i></p> <ul style="list-style-type: none"> <li>• <i>Introduction of a smaller-sized hip prosthesis or fracture fixation screw that differs significantly from predicate designs.</i></li> <li>• <i>Addition of urine as a specimen type in the intended use for a creatinine test.</i></li> <li>• <i>Adjustment of ventilator flow rate to allow use in</i></li> </ul>	<b>Significant</b>	<ul style="list-style-type: none"> <li>• Pre-clinical study reports.</li> <li>• Risk management report.</li> <li>• Clinical evaluation reports.</li> <li>• Software validation report (<i>for software devices</i>).</li> <li>• Labelling.</li> <li>• Change approval documents from recognised countries.</li> </ul>


Flowchart Change No.	Description	Change Category	Supporting Documents
	<p><i>paediatric patients in addition to adults.</i></p> <ul style="list-style-type: none"> <li>• <i>Addition of a transducer in an ultrasound system, expanding intended use for trans-cardiac applications.</i></li> </ul>		
<b>Change B3</b>	<p>Change in Design Characteristics/Specifications Requiring Additional Pre-Clinical and/or Clinical Data, identified new risks that adversely affect the safety and/or performance of the device.</p> <p><i>Examples include: Addition of new connectivity features (e.g., Bluetooth, Wi-Fi) to devices.</i></p>	<b>Significant</b>	<ul style="list-style-type: none"> <li>• Pre-clinical study reports.</li> <li>• Clinical evaluation report.</li> <li>• Risk management report.</li> <li>• Software validation report (<i>for software devices</i>).</li> <li>• Detailed summary of software changes (<i>for software devices</i>).</li> <li>• Labelling.</li> <li>• Change approval documents from recognised countries.</li> </ul>
<b>Change B4</b>	<p>Results of risk analysis conducted during the design validation process identifies new safety and/or performance issues.</p> <p>Examples include:</p> <ul style="list-style-type: none"> <li>• <i>Change from an internal direct current (DC) power source to an external alternating current (AC) source, or vice versa.</i></li> <li>• <i>During clinical validation, durability issues are found with ceramic dental caps,</i></li> </ul>	<b>Significant</b>	<ul style="list-style-type: none"> <li>• Pre-clinical study reports.</li> <li>• Clinical evaluation report.</li> <li>• Risk management report.</li> <li>• Labelling.</li> <li>• Change approval documents from recognised countries.</li> </ul>

Flowchart Change No.	Description	Change Category	Supporting Documents
	<p><i>requiring consideration of alternative materials.</i></p> <ul style="list-style-type: none"> <li>• <i>Change to the cable design and grip of a steerable ablation catheter, resulting in improved deliverability and procedural times.</i></li> </ul>		
	<p>Changes to the design, manufacturing, or components that modify intended performance without introducing new risks affecting safety or performance.</p> <p><i>Examples include: Change of on/off button design or shape to improve ergonomics; additional pre-clinical evaluation is conducted, but no new risks are identified.</i></p>	<b>Non-Significant</b>	N/A
<p><b>Flowchart B</b></p> <p><i>Note: these example of non-significant changes do not affect safety and performance, hence no notification required</i></p>	<p>Other changes to design and specifications that do not affect device safety or performance.</p> <p><i>Examples include, but are not limited to:</i></p> <ul style="list-style-type: none"> <li>• <i>Change of colour of the cap of a reagent.</i></li> <li>• <i>Changes to smartphones, computers, or tablets used with the device (design or operating platform/firmware) without affecting the medical software.</i></li> <li>• <i>Changes to storage media (CD, USB, Web,</i></li> </ul>	<b>Non-Significant</b>	N/A

Flowchart Change No.	Description	Change Category	Supporting Documents
	<p><i>etc.) for standalone software without altering the medical software.</i></p> <ul style="list-style-type: none"> <li>• <i>Change in the shape or location of handles, buttons, or other components without affecting mechanical or electrical safety.</i></li> <li>• <i>Change of design specification tolerances within validated ranges without creating new features.</i></li> <li>• <i>Addition of a touchscreen button replacing a physical button.</i></li> <li>• <i>Change of connector design due to ISO updates.</i></li> <li>• <i>Design changes solely to improve ergonomics or aesthetics, such as:</i> <ul style="list-style-type: none"> <li>○ <i>Change of device surface colour with no patient contact.</i></li> <li>○ <i>Modification of device surface lift (appearance only).</i></li> <li>○ <i>Minor change to on/off button colour for aesthetic improvement.</i></li> <li>○ <i>Change to the design of a handle to improve user experience (e.g., easier or more comfortable to hold).</i></li> </ul> </li> </ul>		

NOTE: Please provide a justification if supporting documents cannot be provided.

**FLOWCHART C**



**Figure B.3: Flowchart C- Change to Sterilisation Facility and its Process and/or Quality Management System**

**Table B.3: Flowchart C - Examples of Changes and Required Supporting Documentation**

Flowchart Change No.	Description	Change Category	Supporting Documents
<b>Change C1</b>	<p>Changes that increase the bioburden alert or action levels, or introduce organisms that are more difficult to eliminate.</p> <p><i>Examples include: Addition of pre-sterilisation transport steps.</i></p>	<b>Significant</b>	<ul style="list-style-type: none"> <li>• Sterilization validation report.</li> <li>• Risk management report.</li> <li>• Change approval documents from recognised countries.</li> </ul>
<b>Change C2</b>	<p>Changes to device design or materials that introduce features that are more difficult to sterilize or alters sterilization parameter.</p> <p><i>Examples include:</i></p> <ul style="list-style-type: none"> <li>• <i>Change to packaging where a single-pouched sterile device is placed into a double pouch.</i></li> <li>• <i>Changes in packaging characteristics, configuration, or density that could affect sterilant absorption/penetration, residue levels (where applicable), or overall sterilization effectiveness, in addition to the safety of the sterile device.</i></li> <li>• <i>change in aeration or dwelling period for EO sterilization.</i></li> </ul>	<b>Significant</b>	<ul style="list-style-type: none"> <li>• Sterilization validation report.</li> <li>• Risk management report.</li> <li>• Packaging validation report.</li> <li>• Change approval documents from recognised countries.</li> </ul>
<b>Change C3</b>	Changes in the sterilisation method or process for a medical device that do not	<b>Significant</b>	<ul style="list-style-type: none"> <li>• Sterilization validation report.</li> <li>• Risk management report.</li> </ul>

Flowchart Change No.	Description	Change Category	Supporting Documents
	<p>provide equivalent or better assurance of sterility and have not been reviewed in previous applications for similar devices.</p> <p><i>Examples include:</i></p> <ul style="list-style-type: none"> <li>• <i>Change in sterilisation method from ethylene oxide to gamma radiation.</i></li> <li>• <i>Changes in the density or configuration of the sterilization load.</i></li> <li>• <i>Changes to quality control verification and validation processes, such as introducing parametric release.</i></li> <li>• <i>Change in moist heat sterilisation parameters.</i></li> <li>• <i>Transition from standard steam sterilisation to pre-vacuum steam cycles to improve steam penetration and eliminate air pockets.</i></li> <li>• <i>Adjustment of gamma radiation sterilisation dose (e.g., from 25 kGy to 30 kGy), with additional validation.</i></li> <li>• <i>Enhanced dose mapping to ensure uniform radiation distribution, providing equivalent or improved sterility.</i></li> <li>• <i>Change in sterilisation load size (e.g., from 8 pallets to 10 pallets) with no change in sterilisation parameters,</i></li> </ul>		<ul style="list-style-type: none"> <li>• QMS certificate(s).</li> <li>• Labelling.</li> <li>• Change approval documents from recognised countries.</li> </ul>


Flowchart Change No.	Description	Change Category	Supporting Documents
	<p><i>accompanied by additional validation.</i></p> <ul style="list-style-type: none"> <li><i>Change in sterilisation process and/or addition/change of sterilisation site.</i></li> </ul>		
<b>Change C4</b>	<p>Changes in the sterile primary packaging where the risk assessment concludes a potential impact on sterility, and the change has not been reviewed in previous applications for similar devices.</p> <p><i>Examples include:</i></p> <ul style="list-style-type: none"> <li><i>Removal of tray from sterile packaging, or change from foil laminate to Tyvek pouch.</i></li> <li><i>Original heat-sealing package barrier found to have a risk of leakage, requiring a change to the sterile packaging barrier.</i></li> <li><i>Change in primary packaging material that may impact sterility, with additional validation conducted; material has not been previously reviewed.</i></li> </ul>	<b>Significant</b>	<ul style="list-style-type: none"> <li>Design verification and validation documents.</li> <li>Risk management report.</li> <li>Clinical evidence.</li> <li>Labelling.</li> <li>Change approval documents from recognised countries.</li> </ul>
<b>Notification C5</b>	Changes to the sterilisation site's name or address (administrative changes without site relocation), or the addition of a sterilisation	<b>Non-Significant, Notification Required</b>	<ul style="list-style-type: none"> <li>QMS certificate(s).</li> <li>Declaration confirming no change to sterilisation process.</li> </ul>

Flowchart Change No.	Description	Change Category	Supporting Documents
	<p>site without any change to the sterilisation process.</p> <p><i>Examples include:</i></p> <ul style="list-style-type: none"> <li>• <i>Transfer of sterilisation activities from Location A to Location B with no change to sterilisation process.</i></li> <li>• <i>Qualification of an additional sterilisation site for a medical device, where the sterilisation process and parameters are exact duplicates of existing sites.</i></li> </ul>		
<p><b>Flowchart C</b></p> <p><i>Note: these example of non-significant changes do not affect safety and performance, hence no notification required</i></p>	<p>Changes to sterilisation processes that do not introduce new risks to device safety or efficacy.</p> <p><i>Examples include:</i></p> <ul style="list-style-type: none"> <li>• <i>Change from Biological Indicator/Batch Release to Parametric Release, with risk assessment confirming no additional risks to product safety or efficacy.</i></li> <li>• <i>Change from a pre-blended sterilant (EtO and CHCs) to EtO post-blended with nitrogen, with the ultimate EtO concentration remaining the same in both cycles.</i></li> <li>• <i>Change from using air (80% nitrogen, 20% oxygen) to pure nitrogen in the aeration</i></li> </ul>	<b>Non-Significant</b>	N/A

Flowchart Change No.	Description	Change Category	Supporting Documents
	<p><i>process to avoid explosive gas mixtures.</i></p> <ul style="list-style-type: none"><li><i>• Change in sterilisation load (e.g., from 8 pallets to 10 pallets) in the same chamber, with no change in sterilisation parameters and within validated range.</i></li><li><i>• Change in aeration time post-sterilisation to reduce EtO content, aligning with other products, with no impact on safety or performance.</i></li></ul>		

NOTE: Please provide a justification if supporting documents cannot be provided.

**FLOWCHART D**



**Figure B.4: Flowchart D - Changes to Software for Medical Devices**

**Table B.4: Flowchart D - Examples of Changes and Required Supporting Documentation**

Flowchart Change No.	Description	Change Category	Supporting Documents
<b>Change D1</b>	<p>All changes to a PCCP that was previously approved during initial registration, including but not limited to:</p> <ul style="list-style-type: none"> <li>• <i>Description of change</i></li> <li>• <i>Change plan/protocol</i></li> <li>• <i>Impact assessment</i></li> </ul>	<b>Significant</b>	<ul style="list-style-type: none"> <li>• Supporting documentation for the new PCCP including description of change, protocol and impact assessment.</li> <li>• Change approval documents from recognised countries.</li> </ul>
<b>Change D2</b>	<p>Changes to software that affect the control of the device and may alter its diagnostic or therapeutic function.</p> <p><i>Examples include:</i></p> <ul style="list-style-type: none"> <li>• <i>Software changes affecting critical steps for laser delivery in eye treatment.</i></li> <li>• <i>Software changes in insulin pumps that enable insulin dosage to be controlled based on readings from compatible continuous blood glucose monitors.</i></li> </ul>	<b>Significant</b>	<ul style="list-style-type: none"> <li>• Software validation report.</li> <li>• Risk management report.</li> <li>• Labelling.</li> <li>• Clinical evaluation report.</li> <li>• Change approval documents from recognised countries.</li> </ul>
<b>Change D2</b>	<p>Changes in software that add new device indications which may alter the diagnostic or therapeutic function.</p> <p><i>Example include: The intended purpose of the device remains unchanged, but the user group is expanded to include paediatric patients.</i></p>	<b>Significant</b>	<ul style="list-style-type: none"> <li>• Software validation report.</li> <li>• Risk management report.</li> <li>• Labelling.</li> <li>• Clinical evaluation report.</li> <li>• Change approval documents from recognised countries.</li> </ul>

Flowchart Change No.	Description	Change Category	Supporting Documents
<b>Change D3</b>	<p>Changes to software initiated by the manufacturer that modify the algorithm and affect the diagnostic or therapeutic function of the device.</p> <p><i>Examples include:</i></p> <ul style="list-style-type: none"> <li>• <i>X-ray lung nodule assessment software updates that improve detection rates for small nodules.</i></li> <li>• <i>Software changes modifying QC interpretation or cut-off calculations of an IVD device.</i></li> <li>• <i>Algorithm changes to an X-ray system with enhanced sensitivity to improve lesion detection.</i></li> </ul>	<b>Significant</b>	<ul style="list-style-type: none"> <li>• Software validation report.</li> <li>• Risk management report.</li> <li>• Clinical evaluation report.</li> <li>• Labelling.</li> <li>• Change approval documents from recognised countries.</li> </ul>
<b>Change D4</b>	<p>Changes to software that introduce new features or applications impacting the diagnostic or therapeutic functions of a medical device.</p> <p><i>Examples include:</i></p> <ul style="list-style-type: none"> <li>• <i>Insulin pump software updated to allow wireless communication with compatible blood glucose monitors.</i></li> <li>• <i>Software change enabling a blood oxygen monitor to also report blood CO<sub>2</sub> concentrations.</i></li> </ul>	<b>Significant</b>	<ul style="list-style-type: none"> <li>• Software validation report.</li> <li>• Risk management report.</li> <li>• Clinical evaluation Report.</li> <li>• Labelling.</li> <li>• Change approval documents from recognised countries.</li> </ul>
<b>Change D4</b>	A software change that alters the way data is read or interpreted by the user, such that the patient's diagnosis or	<b>Significant</b>	<ul style="list-style-type: none"> <li>• Software validation report.</li> <li>• Risk management report.</li> <li>• Labelling.</li> </ul>

Flowchart Change No.	Description	Change Category	Supporting Documents
	treatment may differ compared to the previous software version.		<ul style="list-style-type: none"> <li>• Clinical evaluation Report.</li> <li>• Change approval documents from recognised countries.</li> </ul>
<b>Change D5</b>	<p>Changes to software that add or remove alarm functions, where the user's response to these alarms may affect patient treatment.</p> <p><i>Examples include:</i></p> <ul style="list-style-type: none"> <li>• <i>Addition of an early-warning alarm in an electrocardiogram system to signal a potential cardiac event such as atrial fibrillation.</i></li> <li>• <i>Modification of software to add or remove alarms used to monitor diagnostic procedures on an infectious disease analyzer.</i></li> </ul>	<b>Significant</b>	<ul style="list-style-type: none"> <li>• Software validation report.</li> <li>• Clinical evaluation report.</li> <li>• Risk management report.</li> <li>• Labelling.</li> <li>• Change approval documents from recognised countries.</li> </ul>
<b>Change D6</b>	<p>Software changes that affect the safety, performance, or effectiveness of a registered medical device and may alter patient diagnosis or treatment.</p> <p><i>Examples include:</i></p> <ul style="list-style-type: none"> <li>• <i>A software update to a blood oxygen monitor enabling more accurate reporting of blood CO<sub>2</sub> concentrations (e.g., improved accuracy up to 0.5% deviation).</i></li> <li>• <i>A software upgrade that changes the performance characteristics, such as specificity or sensitivity of an</i></li> </ul>	<b>Significant</b>	<ul style="list-style-type: none"> <li>• Software validation report.</li> <li>• Clinical evaluation report.</li> <li>• Pre-clinical study reports (e.g: validation, usability, etc.).</li> <li>• Risk management report.</li> <li>• Labelling.</li> <li>• Change approval documents from recognised countries.</li> </ul>

Flowchart Change No.	Description	Change Category	Supporting Documents
	<i>in vitro diagnostic medical device.</i>		
<b>Change D6</b>	<p>Software changes that affect the operating performance, processing time, or processing conditions of IVD analyzers.</p> <p><i>Examples include:</i></p> <ul style="list-style-type: none"> <li>• <i>Software updates that enhance the sensitivity of the detector or sensor.</i></li> <li>• <i>Software changes that support increased throughput of the IVD analyzer.</i></li> </ul>	<b>Significant</b>	<ul style="list-style-type: none"> <li>• Software validation report.</li> <li>• Risk management report.</li> <li>• Labelling.</li> <li>• Change approval documents from recognised countries.</li> </ul>
<b>Change D7</b>	<p>Software changes that involve a change to the operating system platform or OS version, where such changes may affect device functionality or compatibility.</p> <p><i>Examples include:</i></p> <ul style="list-style-type: none"> <li>• <i>Software change combined with an operating system change from Linux to Windows or another platform.</i></li> <li>• <i>Addition or modification of OS version(s) that are not backward compatible, such as a transition from Windows to iOS.</i></li> </ul>	<b>Significant</b>	<ul style="list-style-type: none"> <li>• Software validation report.</li> <li>• Risk management report.</li> <li>• Labelling.</li> <li>• Change approval documents from recognised countries.</li> </ul>
<b>Notification D8</b>	<p>Changes involving software version updates that require a new identifier, without impacting device safety or performance.</p> <p><i>Example include: SW 1.1 → SW 1.1.1 / SW 1.2</i></p>	<b>Non-Significant, Notification Required</b>	<ul style="list-style-type: none"> <li>• List of configurations.</li> <li>• Labelling.</li> </ul>
<b>Notification D9</b>	Other software changes that do not fall under the Significant or	<b>Non-</b>	<ul style="list-style-type: none"> <li>• Any supporting document related to</li> </ul>


Flowchart Change No.	Description	Change Category	Supporting Documents
	Non-Significant notifications described above, but for which the establishment intends to update the information in MeDC@St. This submission is optional.	<b>Significant, Notification Optional</b>	the non-significant software change that the establishment intends to update in MeDC@St.
<b>Flowchart D</b>  <i>Note: these example of non-significant changes do not affect safety and performance, hence no notification required</i>	Changes to software where an innovative pathway, such as PCCP has been used and approved during initial registration.	<b>Non-Significant</b>	N/A
	Software changes that require re-validation of assay or test kit specifications but do not affect the safety or performance of the device.  <i>Examples include:</i> <ul style="list-style-type: none"> <li>• <i>Software adjustments to calibration of an IVD analyzer.</i></li> <li>• <i>Software updates to support a new cartridge design.</i></li> </ul>	<b>Non-Significant</b>	N/A
	Other changes related to software that do not impact the safety and/or performance of the medical device, including but not limited to:  <i>Examples include:</i> <ul style="list-style-type: none"> <li>• <i>Simple bug fixes to correct display errors in software analysis results.</i></li> <li>• <i>Software changes introducing non-therapeutic/non-diagnostic features, e.g., printing, faxing, improved image clarity, or reporting format.</i></li> </ul>	<b>Non-Significant</b>	N/A

Flowchart Change No.	Description	Change Category	Supporting Documents
	<ul style="list-style-type: none"> <li>• <i>Disabling software functions that do not interact with other functions.</i></li> <li>• <i>Addition, change, or deletion of OS version(s) within the same platform (e.g., adding Windows X for a product originally using Windows 7).</i></li> <li>• <i>Changes to alter colors or locations of menus on the GUI without affecting safety or performance.</i></li> <li>• <i>Addition of languages for users without altering intended use, principle of operation, or performance.</i></li> <li>• <i>Changes in software distribution or storage methods (USB, CD, DVD, downloads, etc.).</i></li> <li>• <i>Cybersecurity improvements, e.g., adding encryption to configuration files, adding passcodes for remote access, adding timeouts, or adjusting restricted user access.</i></li> <li>• <i>Software changes to prevent invalid characters in barcode inputs.</i></li> <li>• <i>Software updates restoring DICOM conformance to fetch prior studies automatically via PACS.</i></li> <li>• <i>Correcting bottle size parameters in cleaning solutions to prevent fluid detection errors.</i></li> <li>• <i>IVD analyzer software modifications to ensure new reagent data does not merge with existing tables.</i></li> <li>• <i>Code modifications to correct wording or minor</i></li> </ul>		

Flowchart Change No.	Description	Change Category	Supporting Documents
	<p><i>logic errors without altering core detection/measurement algorithms.</i></p> <ul style="list-style-type: none"> <li>● <i>Adjustments to Machine Learning datasets without changing labeled product design specifications.</i></li> <li>● <i>Software changes that correct inadvertent logic errors without safety risk.</i></li> <li>● <i>Modifications to user interface appearance with negligible impact on diagnosis or therapy</i></li> <li>● <i>Updates to software information symbols and details without affecting safety or performance.</i></li> <li>● <i>Allowing new connections to barcode readers, handheld devices, or other devices.</i></li> </ul>		

NOTE: Please provide a justification if supporting documents cannot be provided.

**FLOWCHART E1**



**Figure B.5: Flowchart E1- Changes in Materials for General Medical Devices**

**Table B.5: Flowchart E1- Examples of Changes and Required Supporting Documentation**

Flowchart Change No.	Description	Change Category	Supporting Documents
<b>Change E1.1</b>	<p>Changes to the radiation source used in a medical device.</p> <p><i>Example: radioisotopes</i></p>	<b>Significant</b>	<ul style="list-style-type: none"> <li>● Information on radiation source.</li> <li>● Radiation safety test</li> <li>● Pre-clinical study reports.</li> <li>● Clinical evaluation report.</li> <li>● Risk management report.</li> <li>● Change approval documents from recognised countries.</li> </ul>
<b>Change E1.2</b>	<p>Changes to the type, source, processing, or supplier of biological materials (including cells, tissues, or derivatives of animal, human, microbial, or recombinant origin) without changing the intended use of the biological material.</p> <p><i>Examples include:</i></p> <ul style="list-style-type: none"> <li>● <i>Change in source of hyaluronic acid from Streptococcus zooepidemicus to Streptococcus equi.</i></li> <li>● <i>Conversion from a polymer-sheathed hypotube to a bare, uncoated stainless steel hypotube.</i></li> </ul> <p><i>Note: Changes involving the supplier of unprocessed biological material/tissue do not require submission.</i></p>	<b>Significant</b>	<ul style="list-style-type: none"> <li>● Pre-clinical study reports.</li> <li>● Clinical evaluation report.</li> <li>● Risk management report.</li> <li>● Change approval documents from recognised countries.</li> </ul>
<b>Change E1.3</b>	Changes to material or material formulation of non-biological origin, including	<b>Significant</b>	<ul style="list-style-type: none"> <li>● Pre-clinical study reports.</li> </ul>


Flowchart Change No.	Description	Change Category	Supporting Documents
	<p>changes to device coating or surface modification techniques, for medical devices that are intended to make direct or indirect contact with body tissues and fluids or are absorbed by the body.</p> <p><i>Example include: Change of material for a cardiovascular catheter in contact with body tissue (e.g., change to/from polyether block amide (PEBA), polyamide, or polyether ether ketone (PEEK)).</i></p>		<ul style="list-style-type: none"> <li>● Clinical evaluation report.</li> <li>● Risk management report.</li> <li>● Labelling.</li> <li>● Change approval documents from recognised countries.</li> </ul>
<b>Change E1.4</b>	<p>Changes to materials used for shielding in medical devices that emit ionising radiation.</p> <p><i>Examples include: Change in shielding material of an X-ray system from lead to tungsten.</i></p>	<b>Significant</b>	<ul style="list-style-type: none"> <li>● Information on materials used for radiation shielding.</li> <li>● Radiation safety test.</li> <li>● Risk management report.</li> <li>● Labelling.</li> <li>● Change approval documents from recognised countries.</li> </ul>
<b>Change E1.5</b>	<p>Changes to the type, concentration, or specification of medicinal substances in medical devices that incorporate medicinal substances in an ancillary role, without altering the finished device specifications.</p> <p><i>Examples include:</i></p> <ul style="list-style-type: none"> <li>● <i>Change in the concentration of the drug in a drug-eluting stent.</i></li> <li>● <i>Change in the concentration of antibiotics</i></li> </ul>	<b>Significant</b>	<ul style="list-style-type: none"> <li>● Evidence demonstrating no change to finished device specifications.</li> <li>● Risk management report.</li> <li>● Clinical evaluation report.</li> <li>● NPRA variation approval letter.</li> </ul>

Flowchart Change No.	Description	Change Category	Supporting Documents
	<p><i>or substitution with a different antibiotic in a catheter coated with antibiotic.</i></p>		
<p><b>Flowchart E1</b></p> <p><i>Note: these example of non-significant changes do not affect safety and performance, hence no notification required</i></p>	<p>Changes in material formulation that involve only the change or removal of non-critical materials, such as pigments or processing aids, without affecting finished product specifications or device performance.</p> <p><i>Examples include:</i></p> <ul style="list-style-type: none"> <li>• <i>Change in supplier or vendor of a material, provided it meets the manufacturer's previously reviewed specification.</i></li> <li>• <i>Introduction of a colorant change into the flush port of a PICC (Peripherally Inserted Central Catheter); the flush port is not intended for fluid administration or withdrawal.</i></li> <li>• <i>Change in coating material formulation of a balloon catheter (e.g., increase of surfactant from 1% to 2%) with no change to finished product specifications and no direct patient contact.</i></li> <li>• <i>Change of material formulation to aid manufacturing process, not retained in the final product, with no change to finished product specifications or patient contact.</i></li> </ul>	<p><b>Non-Significant</b></p>	<p>N/A</p>

Flowchart Change No.	Description	Change Category	Supporting Documents
	<ul style="list-style-type: none"> <li>Removal of pigment with no impact on material formulation or finished product specifications.</li> </ul>		

NOTE: Please provide a justification if supporting documents cannot be provided.

**FLOWCHART E2**



**Figure B.6: Flowchart E2- Changes in Materials for In Vitro Diagnostic (IVD) Medical Devices**

**Table B.6: Flowchart E2 - Examples of Changes and Required Supporting Documentation**


Flowchart Change No.	Description	Change Category	Supporting Documents
<b>Change E2.1</b>	<p>Changes in material that result in alteration of performance specifications of the device or IVD test kit.</p> <p><i>Examples include:</i></p> <ul style="list-style-type: none"> <li>• <i>Formulation changes of reagents (e.g., buffer concentration adjustments, addition of preservatives).</i></li> <li>• <i>Changes in synthesis or purification methods of biological components.</i></li> <li>• <i>Conversion from liquid to solid reagent or vice versa; change from RIA to non-RIA methods.</i></li> <li>• <i>Material changes to meet regulatory requirements, e.g., removal of OPE/NPE components from IVD reagents to comply with REACH requirement in the EU, with no change in performance specification.</i></li> <li>• <i>Conversion of primary antibodies in IVD reagents from hybridoma to recombinant products with performance specification changes.</i></li> </ul>	<b>Significant</b>	<ul style="list-style-type: none"> <li>• Pre-clinical study report.</li> <li>• Clinical performance report.</li> <li>• Risk management report.</li> <li>• Labelling.</li> <li>• Change approval documents from recognised countries.</li> </ul>
<b>Change E2.1</b>	<p>Changes to the materials of an IVD that result in a change to the operating principle of the product.</p> <p><i>Note: alters the performance specs of IVD including change to</i></p>	<b>Significant</b>	<ul style="list-style-type: none"> <li>• Pre-clinical study report.</li> <li>• Clinical performance report.</li> <li>• Risk management report.</li> <li>• Labelling.</li> </ul>

Flowchart Change No.	Description	Change Category	Supporting Documents
	<p><i>the operating principle of the product.</i></p> <p><i>Examples include: Change from Immunofluorescence to ELISA.</i></p>		<ul style="list-style-type: none"> <li>• Change approval documents from recognised countries.</li> </ul>
<b>Change E2.2</b>	<p>Changes that require additional testing to confirm that the altered IVD medical device results in changes to registered performance specifications, which may necessitate labelling updates.</p> <p><i>Examples include:</i></p> <ul style="list-style-type: none"> <li>• <i>Change of sources or types of materials (e.g., conjugates, antibodies, antigens, primers, or substrates).</i></li> <li>• <i>Change to sample preparation, such as the inclusion of a stabilizer to simplify preparation or increase sample stability.</i></li> </ul>	<b>Significant</b>	<ul style="list-style-type: none"> <li>• Pre-clinical study report.</li> <li>• Clinical performance report.</li> <li>• Risk management report.</li> <li>• Labelling.</li> <li>• Change approval documents from recognised countries.</li> </ul>
<p><b>Flowchart E2</b></p> <p><i>Note: these example of non-significant changes do not affect safety and performance, hence no notification required</i></p>	<p>Changes in supplier or source of materials where the material continues to meet the manufacturer's previously reviewed specifications and does not affect the device's performance specifications.</p> <p><i>Examples include:</i></p> <ul style="list-style-type: none"> <li>• <i>Change in supplier or vendor of a material with no change in material specification.</i></li> <li>• <i>Change of material source, e.g., magnesium stearate in an IVD reagent from animal to vegetable origin, with no</i></li> </ul>	<b>Non-significant</b>	N/A

Flowchart Change No.	Description	Change Category	Supporting Documents
	<i>change in performance specification.</i>		

NOTE: Please provide a justification if supporting documents cannot be provided.

**FLOWCHART F**



**Figure B.7: Flowchart F- Changes to Labelling of Medical Devices and In Vitro Diagnostic (IVD) Medical Devices**

**Table B.7: Flowchart F - Examples of Changes and Required Supporting Documentation**

Flowchart Change No.	Description	Change Category	Supporting Documents
<b>Change F1</b>	<p>Changes that involve the addition or expansion of explanations or information on the intended use and/or indications for use, without altering the approved scope of the medical device.</p> <p><i>Examples include: Modification of indications for use to exclude femoral implementation, where the exclusion is reflected as a contraindication to ensure safety and effectiveness.</i></p>	<b>Significant</b>	<ul style="list-style-type: none"> <li>• Description of the intended use and/or indication for use.</li> <li>• Labelling.</li> <li>• Clinical evaluation report.</li> <li>• Change approval documents from recognised countries.</li> </ul>
<b>Notification F2</b>	<p>Changes that involve a reduction of intended use or indications for use, not arising due to safety or performance concerns of the medical device.</p>	<b>Non-Significant, Notification Required</b>	<ul style="list-style-type: none"> <li>• Description of the intended use and/or indication for use.</li> <li>• Labelling.</li> </ul>
<b>Change F3</b>	<p>Changes to labelling that involve the addition of warnings, precautions, or contraindications, not prompted by safety or performance concerns of the medical device.</p> <p><i>Examples include: Addition of a contraindication, such as “not for paediatric use.”</i></p>	<b>Significant</b>	<ul style="list-style-type: none"> <li>• Description of the warnings, precautions, and/or contraindications.</li> <li>• Labelling.</li> <li>• Risk management report.</li> <li>• Change approval documents from recognised countries.</li> </ul>

Flowchart Change No.	Description	Change Category	Supporting Documents
<b>Change F3</b>	<p>Changes to labelling that involve the removal of warnings, precautions, or contraindications, not prompted by safety or performance concerns of the medical device.</p> <p><i>Examples include: Deletion of a contraindication, such as “not for paediatric use.”</i></p>	<b>Significant</b>	<ul style="list-style-type: none"> <li>• Description of the warnings, precautions, and/or contraindications.</li> <li>• Labelling.</li> <li>• Risk management report.</li> <li>• Change approval documents from recognised countries.</li> </ul>
<b>Change F4</b>	<p>Changes to the registered method of use that require pre-clinical or clinical data to demonstrate continued safety, performance, and/or effectiveness of the medical device.</p> <p><i>Examples: changes to method of use that changes to IFU</i></p>	<b>Significant</b>	<ul style="list-style-type: none"> <li>• Pre-clinical study report.</li> <li>• Clinical evaluation report.</li> <li>• Software validation report (<i>for software-based devices</i>).</li> <li>• Risk management report.</li> <li>• Labelling.</li> <li>• Change approval documents from recognised countries.</li> </ul>
<b>Change F4</b>	<p>Change in the intended user population from “professional use only” to “home use”, which may impact safety, performance, usability, or effectiveness of the device.</p>	<b>Significant</b>	<ul style="list-style-type: none"> <li>• Pre-clinical study report</li> <li>• Clinical evaluation report.</li> <li>• Software validation report (<i>for software-based devices</i>).</li> <li>• Risk management report.</li> <li>• Labelling.</li> <li>• Change approval documents from recognised countries.</li> </ul>


Flowchart Change No.	Description	Change Category	Supporting Documents
<b>Change F5</b>	Changes to the shelf-life or storage conditions of a medical device	<b>Significant</b>	<ul style="list-style-type: none"> <li>• Shelf life validation/accelerated/real-time stability study report.</li> <li>• Risk management report.</li> <li>• Labelling.</li> <li>• Change approval documents from recognised countries.</li> </ul>
<b>Notification F6</b>	Changes to the manufacturer's name or address on the device labelling that do not affect device safety or performance.	<b>Non-Significant, Notification Required</b>	<ul style="list-style-type: none"> <li>• QMS certificate (s).</li> <li>• Labelling.</li> <li>• Declaration of Conformity.</li> </ul>
<b>Notification F7</b>	Other label/labelling changes that do not fall under previously defined significant or non-significant categories, and which the establishment intends to update in MeDC@St voluntarily.	<b>Non-Significant, Notification Optional</b>	<ul style="list-style-type: none"> <li>• Any supporting document related to the non-significant change that the establishment intends to update in MeDC@St.</li> </ul>
<b>Flowchart F</b>  <i>Note: these example of non-significant changes do not affect safety and performance, hence no notification required</i>	Changes to device labelling or Instruction for Use (IFU) that do not affect device safety, performance, or regulatory information, including but not limited to: <ul style="list-style-type: none"> <li>• <i>Minor wording clarifications in warnings and precautions</i></li> <li>• <i>Correction of typographical errors or grammar</i></li> <li>• <i>Rephrasing or reordering of existing IFU content without changing meaning (e.g., "Avoid exposure to temperature and humidity</i></li> </ul>	<b>Non-Significant</b>	N/A

Flowchart Change No.	Description	Change Category	Supporting Documents
	<p><i>extremes” → “Keep away from sunlight”)</i></p> <ul style="list-style-type: none"> <li>• <i>Changes to make instructions easier, safer, or more effective to follow</i></li> <li>• <i>Addition of languages required by other regulatory jurisdictions</i></li> <li>• <i>Updates to distributor information, including EU authorised representatives, without affecting device registration information</i></li> <li>• <i>Updates to AR label information (e.g., change of AR name or address)</i></li> <li>• <i>Addition/removal of reference agency approvals (e.g., CE Marking)</i></li> <li>• <i>Addition/change/removal of barcodes without affecting the registered device’s List of Configuration (LoC) information.</i></li> <li>• <i>Changes to layout, colour, font sizes, or design without altering prominence or content of labelling.</i></li> <li>• <i>Addition of symbols to product label to align with IFU</i></li> </ul> <p><i>Note: Labelling changes that are not included under the labelling requirements in the Medical Devices Regulations 2012 and ISO 20417:2021 – Medical devices: Information</i></p>		

Flowchart Change No.	Description	Change Category	Supporting Documents
	<i>to be supplied by the manufacturer.</i>		

NOTE: Please provide a justification if supporting documents cannot be provided.

**FLOWCHART G**



**Figure B.8: Flowchart G - Changes to Registered Medical Devices and In Vitro Diagnostic (IVD) Medical Devices registration information**

**Table B.8: Flowchart G - Examples of Changes and Required Supporting Documentation**

Flowchart Change No.	Description	Change Category	Supporting Documents
<p align="center"><b>Change G1</b></p>	<p>Addition of a new medical device (except Class A non-active, non-sterile, or non-measuring accessories) to the List of Configurations of a registered medical device with the same registered common intended use, provided the manufacturer claims that the change does not affect the safety or performance of the device.</p> <p><i>Note: The addition of a new medical device may result in a change of the registered grouping type.</i></p>	<p align="center"><b>Significant</b></p>	<ul style="list-style-type: none"> <li>• Updated list of configurations of the medical device, indicating the name of the affected devices.</li> <li>• Manufacturer declaration.</li> <li>• Regulatory approval documents from recognised countries.</li> <li>• Medical device information including brochure/catalogue.</li> <li>• Labelling.</li> <li>• Declaration of Conformity.</li> <li>• Pre-clinical study reports.</li> <li>• Clinical evaluation report.</li> <li>• Software validation report (<i>for software</i>).</li> <li>• Manufacturing process information.</li> </ul>
<p align="center"><b>Change G1</b></p>	<p>Addition of active, measuring, or sterile Class A medical device accessories that complement the registered medical device as a system.</p> <p><i>Note: The addition of a new medical device may result in a change of the registered grouping type.</i></p>	<p align="center"><b>Significant</b></p>	<ul style="list-style-type: none"> <li>• Updated list of configurations of the medical device, indicating the name of the affected devices.</li> <li>• Regulatory approval documents from recognised countries.</li> <li>• Medical device information including brochure/catalogue.</li> <li>• Labelling.</li> <li>• Declaration of Conformity.</li> </ul>

Flowchart Change No.	Description	Change Category	Supporting Documents
			<ul style="list-style-type: none"> <li>• Pre-clinical study reports.</li> <li>• Software validation report (<i>for software</i>).</li> <li>• Manufacturing process information.</li> </ul>
<b>Notification G2</b>	<p>Addition of Class A medical device accessories that are non-active, have no measuring function, and are non-sterile, complementing the registered medical device as a system.</p> <p><i>Note: The addition of a new medical device may result in a change of the registered grouping type.</i></p>	<b>Non-Significant, Notification Required</b>	<ul style="list-style-type: none"> <li>• Updated list of configurations of the medical device, indicating the name of the affected devices.</li> <li>• Regulatory approval documents from recognised countries.</li> <li>• Medical device information including brochure/catalogue.</li> <li>• Labelling.</li> <li>• Declaration of Conformity.</li> </ul>
<b>Notification G3</b>	<p>Change in the regulatory status of the medical device in recognised countries that were used for product verification during initial registration.</p>	<b>Non-Significant, notification required</b>	<ul style="list-style-type: none"> <li>• Declaration of Conformity.</li> <li>• Labelling.</li> <li>• Reason for status change.</li> </ul>
<b>Notification G4</b>	<p>Deletion of medical device(s) from a list of configuration in registration certificate</p> <p><i>Note:</i>  <i>The medical device is allowed for deletion from the LoC if:</i></p> <ul style="list-style-type: none"> <li>• <i>The medical device has not been placed on the market, is not in commercial distribution, and there are no post-market surveillance (PMS) issues.</i></li> </ul>	<b>Non-Significant, Notification Required</b>	<ul style="list-style-type: none"> <li>• Updated list of configurations of the medical device, indicating the name of the affected devices.</li> <li>• Manufacturer declaration and justification for deletion.</li> <li>• Declaration of Conformity.</li> <li>• Labelling.</li> </ul>

Flowchart Change No.	Description	Change Category	Supporting Documents
	<ul style="list-style-type: none"> <li>The deletion of medical devices may result in a change of the registered grouping type.</li> </ul>		
<b>Notification G4</b>	<p>Changes to the list of configurations of a registered medical device that involve updates to (such as typo or editorial corrections):</p> <ul style="list-style-type: none"> <li>Brief description of item(s)</li> <li>Model or Version Number</li> <li>Identifier</li> </ul>	<b>Non-Significant, Notification Required</b>	<ul style="list-style-type: none"> <li>Updated list of configurations of the medical device, indicating the name of the affected devices.</li> <li>Declaration of Conformity.</li> <li>Labelling.</li> </ul>
<b>Notification G5</b>	Other changes to information in MeDC@St that do not fall under the Significant or Non-Significant notifications described above.	<b>Non-Significant, Notification Optional</b>	<ul style="list-style-type: none"> <li>Any supporting document related to the non-significant change that the establishment intends to update in MeDC@St.</li> </ul>

NOTE: Please provide a justification if supporting documents cannot be provided.

# **MEDICAL DEVICE AUTHORITY**

---

# **MINISTRY OF HEALTH, MALAYSIA**

**Contact Information:**

**MEDICAL DEVICE AUTHORITY**

Ministry of Health Malaysia  
Level 6, Prima 9, Prima Avenue II  
Block 3547, Persiaran APEC  
63000 Cyberjaya, Selangor  
MALAYSIA

T: (03) 8230 0300

F: (03) 8230 0200

Website: <http://www.mda.gov.my>

